secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001213900-24-002360
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt subsidiary Pearsanta acquires MDNA's Mitomic testing platform for ~$25M
------------------------------------------------------------------------------

- Consideration: 50k shares of ADTX common, warrants for 50k shares, 5k Pearsanta preferred ($25M value), up to $3.2M in transition services.
- Amendments to asset purchase agreement removed $500k upfront and $500k closing payments; increased transition services cap from $2.2M to $3.2M.
- Platform includes Mitomic Endometriosis Test (blood-based) and Mitomic Prostate Test; pipeline for ovarian, lung, pancreatic, and other cancers.
- Also amended Merger Agreement with Evofem to extend proxy statement filing deadline to February 14, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390024002360/0001213900-24-002360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390024002360/ea191392-8k425_aditxtinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-002360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer